Free Trial

Regeneron Pharmaceuticals (REGN) Stock Forecast & Price Target

$1,068.94
-0.80 (-0.07%)
(As of 10:27 AM ET)

Regeneron Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 23 Wall Street analysts who have issued ratings for Regeneron Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 23 analysts, 1 has given a sell rating, 4 have given a hold rating, 17 have given a buy rating, and 1 has given a strong buy rating for REGN.

Consensus Price Target

$1,067.23
-0.16% Downside
High Forecast$1,229.00
Average Forecast$1,067.23
Low Forecast$720.00

According to the 23 analysts' twelve-month price targets for Regeneron Pharmaceuticals, the average price target is $1,067.23. The highest price target for REGN is $1,229.00, while the lowest price target for REGN is $720.00. The average price target represents a forecasted downside of -0.16% from the current price of $1,068.94.

TypeCurrent Forecast
7/24/23 to 7/23/24
1 Month Ago
6/24/23 to 6/23/24
3 Months Ago
4/25/23 to 4/24/24
1 Year Ago
7/24/22 to 7/24/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
17 Buy rating(s)
16 Buy rating(s)
15 Buy rating(s)
16 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$1,067.23$998.09$977.77$868.25
Forecasted Upside-0.16% Downside12.42% Upside12.47% Upside14.25% Upside
Get Regeneron Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

REGN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

REGN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Regeneron Pharmaceuticals Stock vs. The Competition

TypeRegeneron PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
2.78
2.72
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside-0.23% Downside3,007.82% Upside9.26% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/22/2024Cantor Fitzgerald
3 of 5 stars
 Boost TargetNeutral ➝ Neutral$925.00 ➝ $1,000.00-6.21%
7/19/2024Piper Sandler
2 of 5 stars
 Boost TargetOverweight ➝ Overweight$1,000.00 ➝ $1,166.00+9.25%
7/18/2024Guggenheim
3 of 5 stars
 Boost TargetBuy ➝ Buy$1,040.00 ➝ $1,180.00+9.34%
7/11/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$1,183.00 ➝ $1,182.00+8.81%
7/10/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$1,050.00 ➝ $1,200.00+12.03%
6/27/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$1,152.00 ➝ $1,152.00+7.78%
6/25/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$1,060.00 ➝ $1,170.00+9.97%
6/24/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$1,229.00 ➝ $1,229.00+16.33%
6/17/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$1,050.00 ➝ $1,150.00+10.44%
5/14/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$1,150.00+17.71%
4/24/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$1,020.00 ➝ $1,030.00+13.25%
4/17/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$1,090.00 ➝ $1,099.00+21.95%
4/12/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderperform ➝ Underperform$710.00 ➝ $720.00-21.77%
4/3/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$1,135.00+18.53%
3/12/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$1,125.00+16.65%
2/5/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$1,055.00 ➝ $1,082.00+14.48%
11/28/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$935.00 ➝ $937.00+17.00%
11/9/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold$800.00-2.77%
11/3/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$950.00+16.02%
9/15/2023Westpark Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageHold
8/21/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$875.00 ➝ $980.00+20.63%
8/21/2023Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Market Perform$950.00 ➝ $1,050.00+29.25%
6/28/202322nd Century Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingDowngrade
6/28/2023500.com
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
6/28/2023VNET Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingDowngrade
6/28/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$800.00 ➝ $760.00+6.13%
5/5/2023888
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
5/5/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$976.00 ➝ $895.00+17.59%
3/28/2023Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
3/27/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
3/23/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$853.00 ➝ $862.00+14.73%
1/30/2023Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$775.00 ➝ $875.00+17.79%
10/3/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$796.00 ➝ $970.00+32.49%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:49 AM ET.

REGN Forecast - Frequently Asked Questions

What is Regeneron Pharmaceuticals' forecast for 2024?

According to the research reports of 23 Wall Street equities research analysts, the average twelve-month stock price forecast for Regeneron Pharmaceuticals is $1,067.23, with a high forecast of $1,229.00 and a low forecast of $720.00.

Should I buy or sell Regeneron Pharmaceuticals stock right now?

23 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There is currently 1 sell rating, 4 hold ratings, 17 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" REGN shares.

Does Regeneron Pharmaceuticals's stock price have much upside?

According to analysts, Regeneron Pharmaceuticals's stock has a predicted upside of 11.57% based on their 12-month stock forecasts.

Has Regeneron Pharmaceuticals been upgraded by Wall Street analysts recently?

Over the previous 90 days, Regeneron Pharmaceuticals's stock had 1 upgrade by analysts.

What analysts cover Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals has been rated by research analysts at Argus, Barclays, Canaccord Genuity Group, Cantor Fitzgerald, Evercore ISI, Guggenheim, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Royal Bank of Canada, and TD Cowen in the past 90 days.

Do Wall Street analysts like Regeneron Pharmaceuticals more than its competitors?

Analysts like Regeneron Pharmaceuticals more than other "medical" companies. The consensus rating score for Regeneron Pharmaceuticals is 2.78 while the average consensus rating score for "medical" companies is 2.72. Learn more on how REGN compares to other companies.


This page (NASDAQ:REGN) was last updated on 7/23/2024 by MarketBeat.com Staff

From Our Partners